Intellia Therapeutics Inc [NTLA] stock is trading at $12.41, up 1.14%. An important factor to consider is whether the stock is rising or falling in short-term value. The NTLA shares have gain 9.92% over the last week, with a monthly amount glided 15.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on April 21, 2025, when Wolfe Research upgraded its rating to a Outperform but kept the price target unchanged to $21 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 05, 2025, and set its price target to $30. On February 28, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $13 on the stock. Goldman downgraded its rating to a Sell but stick to its price target of $9 on February 28, 2025. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $11 on January 27, 2025. Goldman downgraded its rating to Neutral for this stock on February 23, 2024, and downed its price target to $32. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
Intellia Therapeutics Inc [NTLA] stock has fluctuated between $5.90 and $23.76 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $12.41 at the most recent close of the market. An investor can expect a potential return of 12.81% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 52.86M for the trailing twelve months, which represents a growth of 104.76%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -9.69%, Pretax Profit Margin comes in at -9.08%, and Net Profit Margin reading is -9.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.58 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Intellia Therapeutics Inc’s Current Ratio is 5.19. On the other hand, the Quick Ratio is 5.19, and the Cash Ratio is 1.64. Considering the valuation of this stock, the price to sales ratio is 25.20, the price to book ratio is 1.83.
Transactions by insiders
Recent insider trading involved CHASE WILLIAM J, Director, that happened on Aug 20 ’25 when 100000.0 shares were purchased. EVP, Chief Financial Officer, Dulac Edward J III completed a deal on Jul 23 ’25 to sell 7462.0 shares. Meanwhile, EVP, Chief Technical Officer Clark Eliana sold 1022.0 shares on Jul 01 ’25.
